Landos Biopharma, Inc.
LABP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $22,970 | $20,127 | $193,223 | $481,411 |
| - Cash | $37,549 | $36,640 | $8,305 | $2,416 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$14,579 | -$16,513 | $184,918 | $478,995 |
| Revenue | $0 | $0 | $18,000 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$577 | $17,804 | -$137 |
| % Margin | – | – | 98.9% | – |
| EBITDA | -$22,683 | -$39,276 | -$38,620 | -$30,084 |
| % Margin | – | – | -214.6% | – |
| Net Income | -$21,935 | -$37,991 | -$38,226 | -$30,144 |
| % Margin | – | – | -212.4% | – |
| EPS Diluted | -3.5 | -9.44 | -9.5 | -7.51 |
| % Growth | 62.9% | 0.6% | -26.5% | – |
| Operating Cash Flow | -$20,477 | -$45,771 | -$27,061 | -$22,962 |
| Capital Expenditures | $0 | -$7 | -$440 | -$181 |
| Free Cash Flow | -$20,477 | -$45,778 | -$27,501 | -$23,143 |